Cannabis Bioscience International Holdings Files 10-Q

Ticker: CBIH · Form: 10-Q · Filed: Jan 21, 2025 · CIK: 1411057

Cannabis Bioscience International Holdings, INC. 10-Q Filing Summary
FieldDetail
CompanyCannabis Bioscience International Holdings, INC. (CBIH)
Form Type10-Q
Filed DateJan 21, 2025
Risk Levelmedium
Pages14
Reading Time17 min
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, company-information

TL;DR

CBIH filed its 10-Q for Nov 30, 2024. Check financials.

AI Summary

Cannabis Bioscience International Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended November 30, 2024. The company, formerly known as CHINA INFRASTRUCTURE CONSTRUCTION Corp and FIDELITY AVIATION CORP, is incorporated in Colorado and headquartered in Houston, Texas. The filing covers the period after its fiscal year end of May 31.

Why It Matters

This filing provides investors with an update on the company's financial performance and operational status for the quarter ending November 30, 2024.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains financial and operational details that could impact the company's stock, but it does not represent a major event like an acquisition or bankruptcy.

Key Players & Entities

FAQ

What is the exact period covered by this 10-Q filing?

This 10-Q filing is for the quarterly period ended November 30, 2024.

What were the previous names of Cannabis Bioscience International Holdings, Inc.?

The company was formerly known as CHINA INFRASTRUCTURE CONSTRUCTION Corp and FIDELITY AVIATION CORP.

In which state is Cannabis Bioscience International Holdings, Inc. incorporated?

The company is incorporated in Colorado.

What is the principal executive office address of the company?

The principal executive office is located at 6201 Bonhomme Road, Suite 435N, Houston, TX 77036.

What is the IRS Employer Identification Number for the company?

The IRS Employer Identification Number is 84-4901299.

Filing Stats: 4,321 words · 17 min read · ~14 pages · Grade level 16.1 · Accepted 2025-01-21 17:29:17

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 22

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 24

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC. (formerly named China Infrastructure Construction Corp.) CONSOLIDATED BALANCE SHEETS November 30, 2024 May 31, 2024 (Unaudited) (Audited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 1,002 $ 755 Accounts receivable 13,819 20,139 Other current assets 598 598 TOTAL CURRENT ASSETS 15,419 21,492 Right-of-use asset 19,347 35,670 TOTAL ASSETS $ 34,766 $ 57,162 LIABILITIES AND STOCKHOLDERS’ DEFICIENCY CURRENT LIABILITIES Accounts payable and accrued expenses $ 166,119 $ 196,088 Bank overdraft 2,236 2,408 Related party payables 559,488 503,214 Short-term loans (net of amortization of loan fees) 112,629 151,267 SBA loan - current 14,592 7,054 Lease liabilities - current 17,610 21,877 TOTAL CURRENT LIABILITIES 872,674 881,908 LONG-TERM LIABILITIES Notes payable 77,437 – SBA loan 249,500 249,361 Lease liabilities – 4,906 TOTAL LONG-TERM LIABILITIES 326,937 254,267 TOTAL LIABILITIES 1,199,611 1,136,175 STOCKHOLDERS’ DEFICIENCY Authorized 10,000,000 shares of preferred stock, without par value, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock and 2,000 shares have been designated Series B Preferred Stock (2,000 and 1,000 shares outstanding at November 30, 2024, and May 31, 2024, respectively – – Common Stock, without par value: 20,000,000,000 shares authorized; 10,506,749,347 and 10,431,749,347 shares issued and outstanding at November 30, 2024, and May 31, 2024, respectively. – – Additional paid-in capital 4,325,068 4,255,068 Accumulated deficit (5,489,913 ) (5,334,081 ) TOTAL STOCKHOLDERS’ DEFICIENCY (1,164,845 ) (1,079,013 ) TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY $ 34,766 $ 57,162 The accompanying notes are an integral part of these consolidated financial statements. 3 C

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS November 30, 2024 (Unaudited) Note 1 – Organization and Business Organization and Operations Cannabis Bioscience International Holdings, Inc., a Colorado corporation (the “Company”), was formed on February 28, 2003, as a limited liability company under the name Fidelity Aircraft Partners LLC. On December 16, 2009, it converted to a corporation under the name Fidelity Aviation Corporation, and on August 24, 2009, it changed its name to China Infrastructure Construction Corp. On February 28, 2018, the Company changed its name to Hippocrates Direct Healthcare, Inc.; on July 4, 2018, it resumed the name China Infrastructure Construction Corp. On December 6, 2022, it changed its name to its present name. The Company provides educational systems focused on medical cannabis in cities throughout the United States and six countries in Latin America. The Company provides services to third parties in therapeutic areas of clinical trials and conducts clinical trials relating to cannabinoids for its own account. The Company has one non-operating subsidiary, Alpha Fertility and Sleep Center, LLC, a Texas limited liability company, through which it conducted its sleep center business until April 30, 2023. Note 2 – Summary of Significant Accounting Policies Accounting Principles The accompanying unaudited consolidated financial accepted in the United States of America (“U.S. GAAP”) for interim financial statements and with the instructions to Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, they do not contain all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financi

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing